What is Perlara?
Perlara is at the forefront of personalized medicine, offering 'Guided Cures' to help individuals navigate complex treatment pathways. The company leverages a multidisciplinary team of researchers and clinicians, alongside a global research network, to develop bespoke treatment plans. Perlara's services are modality-agnostic, encompassing virtual consulting and drug repurposing, with the ultimate goal of accelerating the discovery of novel therapies. They actively invite participation from families and scientists to foster innovation in medical advancement.
How much funding has Perlara raised?
Perlara has raised a total of $9.4M across 2 funding rounds:
Angel/Seed
$2M
Unspecified
$7.4M
Angel/Seed (2014): $2M, investors not publicly disclosed
Unspecified (2017): $7.4M led by Homebrew Ventures, Y Combinator, Al-Hamra Group, Haystack Fund, Pivotal Capital Alpha, Novartis, and Radical Investments
Key Investors in Perlara
Homebrew Ventures
Homebrew is a venture capital firm based in San Francisco, California, known for investing in early-stage companies.
Y Combinator
Y Combinator is a renowned startup accelerator that provides seed funding and mentorship to early-stage companies, helping them grow and scale.
Novartis
Novartis is a global pharmaceutical giant focused on developing innovative medicines and healthcare solutions, indicating a strategic interest in Perlara's therapeutic development approach.
What's next for Perlara?
The substantial enterprise-level funding, highlighted by a recent major strategic investment, positions Perlara for significant scaling and further development of its innovative Guided Cures platform. This capital infusion is expected to accelerate research collaborations, expand its network of Cure Guides, and enhance its drug repurposing capabilities. Perlara's strategic approach to patient-centric treatment discovery suggests a future focused on forging deeper partnerships within the pharmaceutical and research communities, potentially leading to accelerated clinical trials and the broader application of its personalized medicine model.
See full Perlara company page
